- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | ImmuCell signals operational excellence and targets $30M annual production capacity amid management transition | 2 | Seeking Alpha | ||
| 14.11. | ImmuCell Q3 2025 slides: Improved margins despite revenue dip, Re-Tain awaits FDA | 2 | Investing.com | ||
| 14.11. | ImmuCell: Margen steigen trotz Umsatzrückgang - Warten auf FDA-Zulassung für Re-Tain | 11 | Investing.com Deutsch | ||
| 04.11. | ImmuCell appoints Olivier te Boekhorst as new CEO | 1 | Investing.com | ||
| 07.10. | ImmuCell announces preliminary sales results for Q3 | 1 | Seeking Alpha | ||
| 07.10. | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025 | 90 | GlobeNewswire (Europe) | PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 07.10. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| IMMUCELL Aktie jetzt für 0€ handeln | |||||
| 30.09. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | ImmuCell names Olivier te Boekhorst as new president and CEO | 1 | Investing.com | ||
| 29.09. | ImmuCell Corporation: ImmuCell Announces Selection of its Next President and CEO | 132 | GlobeNewswire (Europe) | PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 25.08. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08. | ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite | 4 | Seeking Alpha | ||
| 14.08. | IMMUCELL CORP /DE/ - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | IMMUCELL CORP /DE/ - 8-K, Current Report | 4 | SEC Filings | ||
| 12.08. | ImmuCell Corporation: ImmuCell Announces Bank Debt Refinancing | 2.693 | GlobeNewswire (Europe) | PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 09.07. | ImmuCell reports 18% sales growth in Q2 2025 | 1 | Investing.com | ||
| 09.07. | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 | 227 | GlobeNewswire (Europe) | PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 09.07. | IMMUCELL CORP /DE/ - 8-K, Current Report | 3 | SEC Filings | ||
| 25.06. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | ImmuCell initiates CEO succession search ahead of planned 2026 retirement | 1 | Seeking Alpha |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,170 | -0,77 % | EQS-PVR: Evotec SE: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Evotec SE
Evotec SE: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
11.12.2025 / 13:55 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BB BIOTECH | 48,400 | +0,31 % | Jade Biosciences secures $45 million in private placement from BB Biotech | ||
| QIAGEN | 38,480 | +1,29 % | QIAGEN NV steht still - für mich ist das kein Stillstand! | ||
| AMGEN | 278,50 | +0,16 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,600 | +0,52 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 146,30 | +0,24 % | HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress | ||
| ILLUMINA | 110,52 | -1,29 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 636,00 | +0,13 % | 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow | ||
| INOVIO PHARMACEUTICALS | 2,240 | +13,13 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,232 | -1,87 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,468 | -3,76 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,780 | +12,66 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| BIOCRYST PHARMACEUTICALS | 6,410 | +0,60 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 44,210 | +0,32 % | BioMarin beruft Rashmi Ramchandani zur neuen Chief Accounting Officer |
Das Unternehmen IMMUCELL CORPORATION kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUCELL CORPORATION finden Sie auf Wallstreet Online.